Of money
All articles
Cannabis reaches the largest health fund in the country
Exclusive: 'Basalt Pharma' won a tender to supply medical cannabis to members of Clalit Health Fund, who constitute about half of its patients in Israel.
In doing so, Clalit joins the Maccabi and Meuhedet HMOs, which also enable the supply of medical cannabis products to their members.
Estimate: Prices are expected to fall
Tags
Clalit Health Services
Medical Cannabis
Cannabis
Maccabi Health Services
United Health Insurance Fund
Clalit Health Services
Roast Greenberg
Thursday, 04 November 2021, 07:36 Updated: 07:54
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
Medical cannabis continues to become mainstream in Israeli medicine: The medical cannabis company Basalt Pharma is the main winner of the Moore Institute's national tender for the supply of medical cannabis products to Clalit Health Fund members.
Under the agreement, Basalt will supply the medical cannabis products to pharmacies nationwide, along with their direct delivery "to the house".
Clalit members are expected to enjoy a tens of percent discount on the prices of various medical cannabis products, and sources in the cannabis field estimate that the tender will lead to price pressures for the entire industry.
More on Walla!
Get to know the most special initiative that currently exists for children with disabilities
To the full article
Basalt Pharma Factory, the main winner of the general tender (Photo: Thea Productions and Design)
50,000 new patients, half of whom are eligible for medical cannabis in Israel
Meir Ariel, CEO of Basalt Pharma, confirms the details, and tells Walla Money! 'That "we approached Clalit's tender with an understanding of the market share that the fund holds. This is a further growth of basalt Parma, and we are excited about its implementation. "
Catchall makes the fund a third that will allow that issue medical marijuana product, after the beginning of the year signed an HMO 'unified' with the company cannabis 'Tikkun Olam' the supply of medical cannabis to its policyholders, its An agreement also with Basalt. And about six months later, Tikun Olam signed a similar agreement with the Maccabi Health Fund, which
also has the largest number of cannabis patients, according to the HQ Medical in the Ministry of Health) for last September about 50,000 people. The other patients are divided between the Maccabi HMO, which contains about 26,000 patients, and Meuhedet with about 9,000 patients.Leumit 'with about 7,500, and about 9,000 additional patients did not belong to any fund at the time of the HQR examination.
Meir Ariel, CEO of Basalt Pharma: "We approached Clalit's tender with an understanding of the market share that the fund holds" (Photo: Thea Productions and Design)
The market will grow, prices will fall
The entry of the HMOs constitutes a medical seal in the field and is expected to increase the number of patients by increasing the number of prescriptions.
The prevailing assumption is that the medical cannabis market will grow by about 50% within just one year from the date of entry of all HMOs into the field.
It should be noted that medical cannabis is not part of the health basket today, and therefore also cannot be subsidized for the insured by the HMOs.
This is why the latter are working to issue tenders and push the companies to a price that is tens of percent lower than the price set for their products.
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
